These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35830214)

  • 1. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
    Zaleska J; Kwasnik P; Paziewska M; Purkot J; Szabelak A; Jurek M; Masny N; Dziatkiewicz I; Pronobis-Szczylik B; Piebiak A; Szymczyk A; Jarosz-Chudzik K; Bolkun L; Kozlowska K; Piszcz J; Subocz E; Halka J; Bator M; Kalicinska E; Wrobel T; Usnarska-Zubkiewicz L; Rybka J; Deren-Wagemann I; Szyca-Smieszniak M; Dybko J; Hus I; Pula B; Cichocka E; Rymko M; Zdunczyk D; Ziarkiewicz M; Basak GW; Bullinger L; Giannopoulos K
    Int J Cancer; 2023 Feb; 152(4):705-712. PubMed ID: 35830214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
    Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
    Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8
    Hernandez SPA; Hersby DS; Munk KK; Tamhane T; Trubach D; Tagliamonte M; Buonaguro L; Gang AO; Hadrup SR; Saini SK
    Front Immunol; 2022; 13():1035344. PubMed ID: 36703960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
    Molica S; Tam C; Polliack A
    Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
    Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
    Benjamini O; Gershon R; Bar-Haim E; Lustig Y; Cohen H; Doolman R; Kedmi M; Ribakovsky E; Kneller A; Hod T; Erez N; Levy I; Rahav G; Avigdor A
    Eur J Haematol; 2023 Jan; 110(1):99-108. PubMed ID: 36208015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Mellinghoff SC; Robrecht S; Sprute R; Mayer L; Weskamm LM; Dahlke C; Gruell H; Teipel F; Schlößer HA; Siepmann K; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Kolovou A; Cornely OA; Eichhorst B; Hallek M; Langerbeins P
    Eur J Haematol; 2024 May; 112(5):788-793. PubMed ID: 38311570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
    Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
    Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Pérez Potti A; Rivera Ballesteros O; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Loré K; Sobkowiak MJ; Gabarrini G; Healy K; Sällberg Chen M; Alici E; Björkström NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren HG
    Mol Med; 2022 Feb; 28(1):20. PubMed ID: 35135470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience.
    Baratè C; Caruso T; Mavilia F; Sammuri P; Pratesi F; Motta G; Guerri V; Galimberti S; Migliorini P
    Clin Exp Med; 2023 Aug; 23(4):1197-1203. PubMed ID: 36074205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.